QIAstat-Dx BCID GN Plus AMR Panel— 510(k) K262168

Substantially Equivalent

QIAGEN GmbH

FDA 510(k) clearance K262168 for QIAstat-Dx BCID GN Plus AMR Panel, Substantially Equivalent on 2026-09-24. Applicant: QIAGEN GmbH. Device class: 2.

Summary

The QIAstat-Dx BCID GN Plus AMR Panel is filed under PEN, gram-negative bacteria and associated resistance markers. That code covers multiplexed in vitro diagnostic tests that detect and identify gram-negative bacteria and resistance markers in positive blood cultures. "AMR" in the name refers to antimicrobial resistance. The record doesn't list the organisms or resistance markers on the panel.

Class II, 21 CFR 866.3365, Microbiology panel, Traditional 510(k).

QIAGEN GmbH filed from Hilden, Germany. Review took 90 days (June 26 to September 24, 2026).

Clearance details

Applicant
QIAGEN GmbH
Product code
Product code PEN
Device class
Class 2
Regulation
21 CFR 866.3365
Advisory panel
Microbiology
Date received
Decision date
Decision
Substantially Equivalent
Clearance type
Traditional
Location
Hilden, DE
Download summary PDFView on FDA.gov ↗

Recent devices under product code PEN

view all

More clearances from QIAGEN GmbH

view all

Adverse events under product code PEN

product code PEN
Death
7
Total
7

Source: openFDA MAUDE database, through . Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.